Table 3.
Patients and disease characteristics at admission
| Patients, n (%) | 35 | ||
|---|---|---|---|
| - Male | 16 (46) | ||
| - Female | 19 (54) | ||
| Median age, years (range) | 66 (42–85) | ||
| Type of cancer, n° of patients | |||
| - SCLC | 15 | ||
| - NSCLC | 7 | ||
| - Rectal adenocarcinoma | 1 | ||
| - Ovary | 1 | ||
| - Breast | 1 | ||
| - Prostate | 1 | ||
| - Ampulloma | 1 | ||
| - Multiple myeloma | 1 | ||
| - Colon | 1 | ||
| - Oesophagus | 1 | ||
| - Refractory diffuse large B-cell Lymphoma | 1 | ||
| - Thymoma | 1 | ||
| - Urothelial | 1 | ||
| - Neuroendocrine | 1 | ||
| - Unknown primary site | 1 | ||
| Vital signs prior tolvaptan treatment, median (range) | |||
| - Weight (kg) | 67 (52–80) (from n= 34) | ||
| - Heart rate (bpm) | 85 (66–100) (from n= 18) | ||
| - Blood pressure (mmHg) | 128 (155–110) – 72 (85–60) (from n= 17) | ||
| Median natremia prior tolvaptan treatment initiation, mmol/L, (range) | 125 (117–130) | ||
| Type of hyponatremia, n° of patients (%) | |||
| - Mild (130–135 mmol/L) | 2 (6) | ||
| - Moderate (120–129 mmol/L) | 31 (88) | ||
| - Severe (Below 120 mmol/L) | 2 (6) | ||
| Patient symptomatic, n° of patients (%) | 26 (74) | ||
| - Headache | 13 (50) | ||
| - Asthenia | 6 (23) | ||
| - Weakness | 4 (15) | ||
| - Dizziness | 4 (15) | ||
| - Confusion | 3 (12) | ||
| - Unsteady gait | 3 (12) | ||
| - Disorientation | 2 (8) | ||
| - Fall | 1 (4) | ||
| - Sleepiness | 1 (4) | ||
| Treatments before Tolvaptan, n° of patients (%) | 11 (31) | ||
| - Fluids restriction | 11 (31) | ||
| - Hypertonic infusion | 3 (9) | ||
| - No prior treatment | 24 (69) | ||
| Results (Tolvaptan) | |||
| Patients monitored after treatment initiation, n° of patients (%) | |||
| - After 4-6h | 13 (37) | ||
| - After 24 hours | 35 (100) | ||
| Days to restore the natremia, n° of patients (%) | |||
| - 1–4 days | 18 (51) | ||
| - More than 4 days | 13 (37) | ||
| - Partial response | 3 (9) | ||
| - No response | 1 (3) | ||
| Adverse events reported, n° of patients | Mild | Moderate | Severe |
| - Thirst | 9 | 3 | 0 |
| - Polyuria | 6 | 4 | 0 |
| - Dry mouth | 4 | 0 | 0 |
| - Hepatic enzymes elevation | 2 | 0 | 0 |
| - Others | 0 | 0 | 0 |
NSCLC no small cell lung cancer, SCLC small cell lung cancer